In short, IGF2BP3 plays an oncogenic role in stabilizing EGFR mRNA in an m6A-dependent manner and further regulates cancer cell proliferation and drug resistance to cetuximab in CRC cells (Fig. 6e). Here, IGF2BP3 is linked to colorectal carcinoma.